The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
- Registration Number
- NCT01795248
- Lead Sponsor
- Tina Vilsboll
- Brief Summary
It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 105
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo, subcutaneous, once-daily for one year Liraglutide Liraglutide 1.8 mg liraglutide, subcutaneous, once-daily for five years
- Primary Outcome Measures
Name Time Method Change in glucose tolerance from baseline to 52 wks, 53 wks, 260 wks, and 261 wks Changes in glucose is measured by area under the curve for the plasma glucose excursion following a 4-hour 75 g oral glucose tolerance test (OGTT)
- Secondary Outcome Measures
Name Time Method Deterioration in glycaemic status from baseline to 52 wks, 53, wks, 260 wks, and 261 wks Percentage of subjects in each treatment arm with normal glucose tolerance (NGT) at inclusion who develop impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) or type 2 diabetes; or with IFG or IGT who develop combined IFG/IGT; or with combined IFG/IGT who develop type 2 diabetes
Trial Locations
- Locations (1)
Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen
🇩🇰Hellerup, Denmark